PVLA — Palvella Therapeutics, Inc.
$125.10-1.02%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for PVLA in the TickerWise workspace.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 14
- Website: https://palvellatx.com
Latest SEC filings for PVLA
Latest PVLA news
- Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference Read article
- Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.